Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants with Advanced Unresectable And/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors

Next Previous
Trial Profile

A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants with Advanced Unresectable And/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NC 410 (Primary) ; Pembrolizumab (Primary)
  • Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver metastases; Oesophageal cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms KEYNOTE-D88
  • Sponsors NextCure

Most Recent Events

  • 16 Dec 2024 Status changed from recruiting to active, no longer recruiting.
  • 07 Nov 2024 According to a NextCure media release, company plans to conclude the current trial and seek a partner to advance the program.
  • 05 Nov 2024 According to a NextCure media release, company to present clinical data from phase 1b portion of this trial at the Society for Immunotherapy of Cancer (SITC) annual meeting on Saturday, November 9, 2024, 7:10-8:30 PM.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top